Clinical trials: Lymphoid Neoplasms
Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
The purpose of this study is to determine if peripheral blood cells collected following AMD3100 mobilization can be used safely for hematopoietic cell transplantation into HLA-matched recipients.
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Lymphocytic Leukemia, Chronic
- Trial name
- NCT00241358
- Testing
- AMD3100, Stem Cell Transplant
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Washington University School of Medicine
Chronic Lymphocytic Leukemia, Leukemia
A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
This research study is evaluating a new drug called ibrutinib in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR) as a possible treatment for Chronic Lymphocytic Leukemia (CLL).
- Trial name
- iFCR (NCT02251548)
- Testing
- Ibrutinib, Fludarabine, Cyclophosphamide
- Where
- 9 sites in United States
- Volunteers
- 85 people
- Sponsor
- Dana-Farber Cancer Institute
Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are…
- Trial name
- NCT00123487
- Testing
- dasatinib
- Where
- 119 sites in United States, Argentina and 30 more
- Volunteers
- 638 people
- Sponsor
- Bristol-Myers Squibb
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors
The study investigates how the COVID-19 pandemic has impacted the psychological, financial, physical, and social well-being of adolescent and young adult (AYA) cancer patients and survivors.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04551378
- Testing
- Quality-of-Life Assessment, Survey Administration
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- M.D. Anderson Cancer Center
ALL, Adult
Optimising Pharmacist-led Medication Reviews in Primary Care
An increasing number of people are diagnosed with long-term conditions and are prescribed medicines to manage these conditions. Medication reviews (MRs) are used to optimise medicines, improve health outcomes, and decrease…
- Trial name
- OPen (NCT05928104)
- Testing
- Medication review
- Where
- 3 sites in United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of East Anglia
Hematopoietic/Lymphoid Cancer, Acute Myeloid Leukemia
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn about the safety and tolerability of 3 different doses of CD33-CAR-T…
- Trial name
- NCT03126864
- Testing
- Leukapheresis, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Acute Lymphoblastic, Lymphoblastic Leukemia, Acute, Childhood
CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
Study Description: This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy.
- Trial name
- NCT05440409
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Extranodal Lymphoma
A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types
The aim of this study is to retrospectively collect clinical information on patients with extranodal or rare lymphomas, and to explore the best treatment strategy for these lymphomas in the real-world population.
- Conditions
- Lymphoma, Extranodal Lymphoma, Diffuse Large B Cell Lymphoma, Anaplastic Large Cell Lymphoma
- Trial name
- NCT05907447
- Testing
- No interventions need to be specified for this study
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Ruijin Hospital
Hematopoietic and Lymphoid Cell Neoplasm
A Multidisciplinary Approach to Improve the Health of Older Adults With Blood Cancers After Stem Cell Transplantation
This clinical trial studies the usefulness and process of a multidisciplinary intervention, where patients see multiple healthcare professionals, aimed at improving fitness and the ability to bounce back after transplant for…
- Trial name
- NCT04914338
- Testing
- Health Promotion, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- City of Hope Medical Center
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
In this study the investigators investigate a cell therapy strategy that could harness allogeneic effectors that can potentially mediate anti-lymphoma effect.
- Trial name
- NCT01181258
- Testing
- Rituximab, Interleukin-2, Natural killer cells
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Chronic Lymphoid Leukemia
Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL
CLL2-BAAG is a prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of debulking with bendamustine followed by induction and maintenance with GA101 (obinutuzumab)…
- Trial name
- CLL2-BAAG (NCT03787264)
- Testing
- Bendamustine, Obinutuzumab, Acalabrutinib
- Where
- 17 sites in Germany
- Volunteers
- 46 people
- Sponsor
- German CLL Study Group
Glioma, Hematopoietic and Lymphoid Cell Neoplasm
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
This study performs standardized testing of tumor tissue samples to learn which genes are mutated (have changed) in order to provide personalized cancer therapy options to cancer patients at MD Anderson.
- Conditions
- Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Melanoma
- Trial name
- NCT01772771
- Testing
- Biospecimen Collection, Genetic Testing, Medical Chart Review
- Where
- United States
- Volunteers
- 12,000 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Neoplasm, Adult ALL
LUS to Assess Lung Injury After Lung Lobectomy
The purpose of the study is to assess whether lung ultrasound is able to detect lung injury after lung resection surgery.
- Conditions
- Lung Neoplasm, Adult ALL, Lung Injury, Lung Inflammation
- Trial name
- OPEN THORUS (NCT04755478)
- Testing
- Thoracotomy, VATS
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital General Universitario de Valencia
Lymphoblastic Lymphoma
Hyper-CVAD Treatment in Lymphoblastic Lymphoma
Treatment outcomes of lymphoblastic lymphoma (LBL) have improved by the use of the regimens for acute lymphoblastic leukemia. Hyper-CVAD is one of the most effective treatments with high remission rate in acute lymphoblastic…
- Trial name
- LBL-CISL-1 (NCT01813344)
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Ajou University School of Medicine
Anemia, Leukemia
Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer
RATIONALE: Epoetin alfa and epoetin beta may cause the body to make more red blood cells. Red blood cells contain iron that is needed to carry oxygen to the tissues.
- Conditions
- Anemia, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00482716
- Testing
- epoetin alfa, epoetin beta, iron dextran complex
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- St. Bartholomew's Hospital
Leukemia, Acute Lymphoblastic, Acute Myeloid Leukemia
GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
Several groups have demonstrated very low incidence of acute and chronic graft-versus-host disease (GVHD) with post-transplantation cyclophosphamide (PTCy) in haploidentical, unrelated and related allogeneic stem cell…
- Conditions
- Leukemia, Acute Lymphoblastic, Acute Myeloid Leukemia, Mixed-Lineage Acute Leukemias
- Trial name
- NCT02799147
- Testing
- Allogeneic stem cell transplantation, Fludarabine monophosphate, Busulfan
- Where
- Russia
- Volunteers
- 27 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Acute Lymphoblastic Leukemia (ALL)
Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TEL/ALM1-positive ALL Relapses (LAL TEL/ALM1 and CD9).
Down regulation of CD9 in TEL/AML1-positive ALL is addressed in motility assays to explore its role in B-ALL pathogenesis and its potential implication in relapses (and prognosis).
- Trial name
- LAL TEL/ALM1 (NCT01282593)
- Testing
- Impact of CD9 expression level on motility assays, Post-transcriptional regulation of CD9
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Rennes University Hospital
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Trial name
- HEM-iSMART C (NCT05745714)
- Testing
- Ruxolitinib, Venetoclax, Dexamethasone
- Where
- 33 sites in Austria, Belgium and 12 more
- Volunteers
- 26 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Bladder Cancer, Brain and Central Nervous System Tumors
Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Esophageal Cancer, Intraocular Melanoma
- Trial name
- NCT00757614
- Testing
- DNA analysis, polymorphism analysis, laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 14,000 people
- Sponsor
- Cancer Research UK
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test
AlloHeme is a chimerism test service that utilizes NGS technology to analyze SNP loci to quantify donor and recipient cells by measuring genomic DNA.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- ACROBAT (NCT04635384)
- Where
- 10 sites in United States
- Volunteers
- 307 people
- Sponsor
- CareDx
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.